Forecast

Buy
  3
Hold
  11
Sell
  2

Discussions in the community

There is no discussion about this asset yet.

Start discussion

  • Galapagos records 91% drop in revenue and launches strategic realignment

    Galapagos reported a 91.3% decline in revenue for Q1 2026 to €6.5 million, primarily due to the loss of income from the agreement with Gilead. Despite the revenue shock, the company posted a net profit of €14.5 million, driven by positive currency effects and financial results. Management announced a comprehensive transformation including a renaming to Lakefront Biotherapeutics, a focus on innovative therapies such as Gamgertamig, and consideration of a share buyback as part of a new Gilead agreement. For 2026, Galapagos expects high expenses (including a prepayment to Gilead and costs related to the acquisition of Ouro Medicines) and forecasts year-end cash of between €1.975 billion and €2.05 billion. » More on de.investing.com


  • RBC cuts Galapagos NV price target to $28, keeps Sector Perform ahead of Q1

    RBC Capital Markets reduced its price target for Galapagos NV from $33 to $28 while maintaining a Sector Perform rating, citing seasonal pressures including reimbursement resets, gross-to-net dynamics, fewer selling days and potential weather-related disruptions. The bank noted that rising M&A activity and clearer drug-pricing expectations could help offset near-term volatility. Separately, Galapagos and Gilead agreed a binding framework related to Gilead’s acquisition of Ouro Medicines that expands collaboration rights and includes funding and operational arrangements. » More on finance.yahoo.com


  • Galapagos signs agreement with Gilead on Ouro Medicines assets

    Galapagos reached a binding agreement with Gilead tied to Gilead’s acquisition of Ouro Medicines, obtaining licenses to key IP, gamgertamig (a BCMAxCD3 T cell engager) and additional preclinical programs, plus related facilities and staff. The deal makes Galapagos responsible for early-stage development while later-stage costs and global commercialization (outside certain territories) will be shared with Gilead; Galapagos can receive milestone payments and tiered royalties of 20–23% on net sales. The company can independently deploy at least $500M of cash, including up to $150M for potential share buybacks. Gamgertamig has FDA Fast Track and Orphan Drug designations for AIHA and ITP and may enter registrational studies as early as 2027. Galapagos also proposed appointing Gino Santini as non-executive independent director and future chair, subject to shareholder approval. » More on finance.yahoo.com


  • Galapagos and Gilead collaborate on Gamgertamig, unlock $500M and target 2027 registrational trials

    Galapagos struck a binding collaboration with Gilead on BCMA x CD3 T‑cell engager Gamgertamig, with the companies splitting an upfront payment and milestone payments (including references to ~$1.675 billion and up to $500 million) and Galapagos eligible for up to $100 million in development milestones. The deal amends the legacy OLCA and unlocks an additional $500 million of Galapagos cash (including up to $150 million potentially available for return of capital); Gilead will hold commercialization rights outside Greater China while Galapagos gets 20%–23% royalties. Gamgertamig is in phase 1b (over 60 autoimmune patients treated, >160 across all trials), has Fast Track and Orphan designations for hemolytic anemia and ITP, and could enter registrational studies as early as 2027. Galapagos will fund development through initiation of registrational studies, after which costs are shared, and management says the transaction preserves strategic flexibility and leaves the majority of cash available for other opportunities. » More on finance.yahoo.com


  • Galapagos exits cell therapy, shifts to business development with ~€3bn cash

    Galapagos is winding down its cell therapy program and refocusing on business development in inflammation & immunology and oncology, backed by a refreshed leadership team and board. The company ended 2025 with about €2.998 billion in cash after recognizing €1.069 billion of deferred income tied to Gilead and taking ~€399.8 million of wind‑down and restructuring charges. TYK2 inhibitor GLPG3667 showed positive Phase 2 topline results in dermatomyositis and SLE, but Galapagos says it lacks full Phase 3 infrastructure and is seeking partners to advance the program. Management expects the cell therapy wind‑down to be largely complete by Q3 2026, anticipates one‑time restructuring cash costs of €125–175 million in 2026, and aims to be cash‑flow neutral to positive by year‑end 2026. » More on finance.yahoo.com

Financials

In the last quarter, Galapagos had revenue of €7.42M and net profit of -€2.61M

(EUR) September 2026
YoY
Revenue 7.42M 89.58%
Gross profit 3.82M 93.67%
Net profit -2.61M 98.71%
EBITDA -39.84M 78.98%

Fundamentals

Metric Value
Market capitalization
€2.11B
Number of shares
65.9M
52-week high/low
€31.99 - €23.88
Dividends No
Beta
0.11
P/E ratio
4.18
PEG ratio
-0.11
P/B ratio
0.63
P/S ratio
1.94

Company profile

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.Ă  r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Name
Galapagos
CEO
Henry Gosebruch
Headquarters Mechelen, bu
Belgium
Website
Sector
Health Care
Industry
Biotechnology
IPO
05/06/2005
Employees 452

Ticker symbols

Exchange Symbol
Euronext
GLPG.AS
Pnk
GLPGF
Amsterdam
GLPG.AS
Frankfurt
GXE.F
DĂĽsseldorf
GXE.DU
London
0JXZ.L
MĂĽnchen
GXE.MU
Wien
GLPG.VI
🍪

Parqet  uses cookies. Learn more